Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 18 years of age and less than or equal to 70~* Chronic plaque psoriasis for at least 6 months prior to Screening~* Psoriasis Area and Severity Index (PASI) \>=12 and body surface area (BSA) \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5-point scale~* Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy~* Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug, and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose~* Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication (anticipated 5 half-lives)~Exclusion Criteria:~* Subjects previously participating in a bimekizumab study~* Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced psoriasis~* History of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline Visit (including herpes zoster)~* High risk of infection in the Investigator's opinion~* Current sign or symptom that may indicate an active infection~* Concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection~* Live (includes attenuated) vaccination within the 8 weeks prior to Baseline~* Subjects with concurrent malignancy or history of malignancy during the past 5 years (except for specific malignant condition as defined in the protocol)~* Primary immunosuppressive conditions~* TB infection, high risk of acquiring TB infection, latent TB infection (LTBI), or current or history of NTMB infection~* Laboratory abnormalities, as defined in the study protocol~* Any condition which, in the Investigator's judgement, would make the subject unsuitable for inclusion in the study~* Exposure to more than 1 biological response modifier (limited to anti-TNF or IL-12/-23) or any biologic response modifier during the three months prior to the Baseline Visit~* Subjects have received previous treatment with any anti-IL-17 therapy for the treatment of psoriasis or psoriatic arthritis~* Subjects with a diagnosis of inflammatory conditions other than psoriasis or psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, or systemic lupus erythematosus. Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease at Screening or Baseline~* Subjects taking psoriatic arthritis medications other than nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm 1 (Type: EXPERIMENTAL): Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
- Treatment Arm 2 (Type: EXPERIMENTAL): Subjects randomized in this arm will receive Bimekizumab injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete